HLA variation and disease

Nature Reviews Immunology

Volumn 18, Issue 5, 2018, Pages 325-339

  Dendrou, Calliope A ^a   Petersen, Jan ^b   Rossjohn, Jamie ^b,c   Fugger, Lars ^d,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BINDING AFFINITY; BINDING SITE; CELL THERAPY; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; VACCINATION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; CHEMISTRY; DISEASES; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC VARIATION; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; PROCEDURES; T LYMPHOCYTE;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; DISEASE; GENE EXPRESSION REGULATION; GENES, MHC CLASS I; GENES, MHC CLASS II; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HLA ANTIGENS; HUMANS; IMMUNOGENETIC PHENOMENA; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN STABILITY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85045958732     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2017.143     Document Type: Review

References (130)

1. Amiel, J. in Study of the Leukocyte Phenotypes in Hodgkin's Disease in Histocompatibility Testing (ed. Teraski, P. I. ) 79-81 (Munksgaard, 1967).
2. Trowsdale, J. & Knight, J. C. Major histocompatibility complex genomics and human disease. Ann. Rev. Genom. Hum. Genet. 14, 301-323 (2013).
3. Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J. & Moody, D. B. The burgeoning family of unconventional T cells. Nat. Immunol. 16, 1114-1123 (2015).
4. Robinson, J., Soormally, A. R., Hayhurst, J. D. & Marsh, S. G. E. The IPD-IMGT/HLA database-new developments in reporting HLA variation. Hum. Immunol. 77, 233-237 (2016).
5. Parham, P. & Ohta, T. Population biology of antigen presentation by MHC class I molecules. Science 272, 67-74 (1996).
6. Carrington, M. et al. HLA and HIV?1: heterozygote advantage and B35?Cw04 disadvantage. Science 283, 1748-1752 (1999).
7. Parham, P. & Moffett, A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat. Rev. Immunol. 13, 133-144 (2013).
8. Sewell, A. K. Why must T cells be cross-reactive? Nat. Rev. Immunol. 12, 668-677 (2012).
9. Quigley, M. F. et al. Convergent recombination shapes the clonotypic landscape of the naive T?cell repertoire. Proc. Natl Acad. Sci. USA 107, 19414-19419 (2010).
10. Saunders, P. M. et al. A bird's eye view of NK cell receptor interactions with their MHC class I ligands. Immunol. Rev. 267, 148-166 (2015).
11. Hudson, L. E. & Allen, R. L. Leukocyte Ig?Like Receptors-a model for MHC class I disease associations. Front. Immunol. 7, 281 (2016).
12. Fadda, L. et al. Peptide antagonism as a mechanism for NK cell activation. Proc. Natl Acad. Sci. USA 107, 10160-10165 (2010).
13. Sim, M. J. et al. Canonical and cross-reactive binding of NK cell inhibitory receptors to HLA?C allotypes is dictated by peptides bound to HLA?C. Front. Immunol. 8, 193 (2017).
14. Miles, J. J., McCluskey, J., Rossjohn, J. & Gras, S. Understanding the complexity and malleability of T?cell recognition. Immunol. Cell Biol. 93, 433-441 (2015).
15. Madsen, L. S. et al. A humanized model for multiple sclerosis using HLA?DR2 and a human T?cell receptor. Nat. Genet. 23, 343-347 (1999).
16. Hahn, M., Nicholson, M. J., Pyrdol, J. & Wucherpfennig, K. W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 6, 490-496 (2005).
17. Bulek, A. M. et al. Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes. Nat. Immunol. 13, 283-289 (2012).
18. Pugliese, A. et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR?IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 15, 293-297 (1997).
19. Cole, D. K. et al. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J. Clin. Invest. 126, 2191-2204 (2016).
20. Yin, Y., Li, Y., Kerzic, M. C., Martin, R. & Mariuzza, R. A. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J. 30, 1137-1148 (2011).
21. Quandt, J. A. et al. Unique clinical and pathological features in HLA?DRB10401?restricted MBP 111?129?specific humanized TCR transgenic mice. J. Exp. Med. 200, 223-234 (2004).
22. Armstrong, K. M., Piepenbrink, K. H. & Baker, B. M. Conformational changes and flexibility in T?cell receptor recognition of peptide-MHC complexes. Biochem. J. 415, 183-196 (2008).
23. Stadinski, B. D. et al. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc. Natl Acad. Sci. USA 107, 10978-10983 (2010).
24. Yang, J. et al. Autoreactive T cells specific for insulin B:11?23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc. Natl Acad. Sci. USA 111, 14840-14845 (2014).
25. Ooi, J. D. et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545, 243-247 (2017).
26. Harkiolaki, M. et al. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity 30, 348-357 (2009).
27. Sethi, D. K. et al. A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC. J. Exp. Med. 208, 91-102 (2011).
28. Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
29. Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A. & Tzoulaki, L. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 14, 263-273 (2015).
30. Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47, 1107-1113 (2015).
31. Nielsen, T. R. et al. Effects of infectious mononucleosis and HLA?DRB115 in multiple sclerosis. Mult. Scler. J. 15, 431-436 (2009).
32. Lang, H. L. E. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940-943 (2002).
33. Babon, J. A. et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat. Med. 22, 1482-1487 (2016).
34. Koning, F., Thomas, R., Rossjohn, J. & Toes, R. E. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Nat. Rev. Rheumatol. 11, 450-461 (2015).
35. Scally, S. W. et al. A molecular basis for the association of the HLA?DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569-2582 (2013).
36. Mohammed, F. et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 9, 1236-1243 (2008).
37. Mannering, S. I. et al. The insulin A?chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 202, 1191-1197 (2005).
38. Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713-717 (1998).
39. Bodd, M., Kim, C. Y., Lundin, K. E. & Sollid, L. M. T?Cell response to gluten in patients with HLA?DQ2. 2 reveals requirement of peptide-MHC stability in celiac disease. Gastroenterology 142, 552-561 (2012).
40. Fallang, L. E. et al. Differences in the risk of celiac disease associated with HLA?DQ2. 5 or HLA?DQ2. 2 are related to sustained gluten antigen presentation. Nat. Immunol. 10, 1096-1101 (2009).
41. Hovhannisyan, Z. et al. The role of HLA?DQ8 ?57 polymorphism in the anti-gluten T?cell response in coeliac disease. Nature 456, 534-538 (2008).
42. Todd, J. A., Bell, J. I. & McDevitt, H. O. HLA?DQ gene contributes to susceptibility and resistance to insulin-dependent diabetes-mellitus. Nature 329, 599-604 (1987).
43. Corper, A. L. et al. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288, 505-511 (2000).
44. Broughton, S. E. et al. Biased T cell receptor usage directed against human leukocyte antigen DQ8?restricted gliadin peptides is associated with celiac disease. Immunity 37, 611-621 (2012).
45. Petersen, J. et al. T?Cell receptor recognition of HLA?DQ2?gliadin complexes associated with celiac disease. Nat. Struct. Mol. Biol. 21, 480-488 (2014).
46. Dieterich, W. et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3, 797-801 (1997).
47. Verpoort, K. N. et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 54, 3799-3808 (2006).
48. Liepe, J. et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354-358 (2016).
49. Hansen, T. H. & Bouvier, M. MHC class I antigen presentation: learning from viral evasion strategies. Nat. Rev. Immunol. 9, 503-513 (2009).
50. Jin, N. et al. N?Terminal additions to the WE14 peptide of chromogranin A create strong autoantigen agonists in type 1 diabetes. Proc. Natl Acad. Sci. USA 112, 13318-13323 (2015).
51. Delong, T. et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351, 711-714 (2016).
52. Raj, P. et al. Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. eLife 5, e12089 (2016).
53. O'Huigin, C. et al. The molecular origin and consequences of escape from miRNA regulation by HLA?C alleles. Am. J. Hum. Genet. 89, 424-431 (2011).
54. Shrestha, D., Szollosi, J. & Jenei, A. Bare lymphocyte syndrome: an opportunity to discover our immune system. Immunol. Lett. 141, 147-157 (2012).
55. Rowe, M. et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl Acad. Sci. USA 104, 3366-3371 (2007).
56. Balan, N., Osborn, K. & Sinclair, A. J. Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding. J. Gen. Virol. 97, 725-732 (2016).
57. Petersdorf, E. W. et al. HLA?C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood 124, 3996-4003 (2014).
58. Petersdorf, E. W. et al. High HLA?DP expression and graft-versus-host disease. N. Engl. J. Med. 373, 599-609 (2015).
59. Ferreira, L. M. R., Meissner, T. B., Tilburgs, T. & Strominger, J. L. HLA?G: at the interface of maternal-fetal tolerance. Trends Immunol. 38, 272-286 (2017).
60. Quach, K., Grover, S. A., Kenigsberg, S. & Librach, C. L. A combination of single nucleotide polymorphisms in the 3' untranslated region of HLA?G is associated with preeclampsia. Hum. Immunol. 75, 1163-1170 (2014).
61. Ljunggren, H. G. et al. Empty MHC class?I molecules come out in the cold. Nature 346, 476-480 (1990).
62. Wearsch, P. A. & Cresswell, P. Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin?ERp57 heterodimer. Nat. Immunol. 8, 873-881 (2007).
63. Williams, A. P., Peh, C. A., Purcell, A. W., McCluskey, J. & Elliott, T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 16, 509-520 (2002).
64. Rizvi, S. M. et al. Distinct assembly profiles of HLA?B molecules. J. Immunol. 192, 4967-4976 (2014).
65. Thammavongsa, V., Raghuraman, G., Filzen, T. M., Collins, K. L. & Raghavan, M. HLA?B44 polymorphisms at position 116 of the heavy chain influence TAP complex minding via an effect on peptide occupancy. J. Immunol. 177, 3150-3161 (2006).
66. Zernich, D. et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J. Exp. Med. 200, 13-24 (2004).
67. Apps, R. et al. Relative expression levels of the HLA class?I proteins in normal and HIV-infected cells. J. Immunol. 194, 3594-3600 (2015).
68. Kaur, G. et al. Structural and regulatory diversity shape HLA?C protein expression levels. Nat. Commun. 8, 15924 (2017).
69. Horowitz, A. et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci. Immunol. 1, eaag1672 (2016).
70. Duggal, P. et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann. Intern. Med. 158, 235-245 (2013).
71. Miyadera, H., Ohashi, J., Lernmark, Å., Kitamura, T. & Tokunaga, K. Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. J. Clin. Invest. 125, 275-291 (2015).
72. Zhou, Z. & Jensen, P. E. Structural characteristics of HLA?DQ that may impact DM editing and susceptibility to type?1 diabetes. Front. Immunol. 4, 262 (2013).
73. Ferreira, R. C. et al. High-density SNP mapping of the HLA region identifies multiple independent susceptibility loci associated with selective IgA deficiency. PLOS Genet. 8, e1002476 (2012).
74. Weinstock, C. et al. Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes. Tissue Antigens 77, 317-324 (2011).
75. Hu, X. L. et al. Additive and interaction effects at three amino acid positions in HLA?DQ and HLA?DR molecules drive type 1 diabetes risk. Nat. Genet. 47, 898-905 (2015).
76. Mignot, E. et al. Complex HLA?DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 68, 686-699 (2001).
77. Cortes, A. et al. Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. Nat. Genet. 49, 1311-1318 (2017).
78. McGonagle, D., Aydin, S. Z., Gul, A., Mahr, A. & Direskeneli, H. MHC-I-opathy-unified concept for spondyloarthritis and Behcet disease. Nat. Rev. Rheumatol. 11, 731-740 (2015).
79. Brown, M. A., Kenna, T. & Wordsworth, B. P. Genetics of ankylosing spondylitis-insights into pathogenesis. Nat. Rev. Rheumatol. 12, 81-91 (2016).
80. Lenz, T. L. et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat. Genet. 47, 1085-1090 (2015).
81. Vader, W. et al. The HLA?DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl Acad. Sci. USA 100, 12390-12395 (2003).
82. Gregersen, J. W. et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443, 574-577 (2006).
83. Sulzer, D. et al. T cells from patients with Parkinson's disease recognize ?-synuclein peptides. Nature 546, 656-661 (2017).
84. Tan, A. T. et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T?cell repertoire. J. Virol. 82, 10986-10997 (2008).
85. Ansari, M. A. et al. Genome-to?genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat. Genet, 49, 666-673 (2017).
86. Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014).
87. Park, S. H. et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat. Med. 19, 1638-1642 (2013).
88. Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152-1158 (2015).
89. McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259-1271. e11 (2017).
90. Marty, R. et al. MHC?1 genotype restricts the oncogenic mutational landscape. Cell 171, 1272-1283. e15 (2017).
91. Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85-95 (2002).
92. Vader, W. et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 122, 1729-1737 (2002).
93. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
94. Dolton, G. et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin. Exp. Immunol. 177, 47-63 (2014).
95. Nepom, G. T. MHC class II tetramers. J. Immunol. 188, 2477-2482 (2012).
96. Newell, E. W. et al. Combinatorial tetramer staining and mass cytometry analysis facilitate T?cell epitope mapping and characterization. Nat. Biotechnol. 31, 623-629 (2013).
97. Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94-98 (2017).
98. Stubbington, M. J. et al. T cell fate and clonality inference from single-cell transcriptomes. Nat. Methods 13, 329-332 (2016).
99. Stadinski, B. D. et al. Hydrophobic CDR3 residues promote the development of self-reactive T cells. Nat. Immunol. 17, 946-955 (2016).
100. Birnbaum, M. E. et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-1087 (2014).
101. Borbulevych, O. Y., Santhanagopolan, S. M., Hossain, M. & Baker, B. M. TCRs used in cancer gene therapy cross-react with MART?1/Melan?A tumor antigens via distinct mechanisms. J. Immunol. 187, 2453-2463 (2011).
102. Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).
103. Beringer, D. X. et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat. Immunol. 16, 1153-1161 (2015).
104. Gras, S. et al. Reversed T cell receptor docking on a major histocompatibility class I complex limits involvement in the immune response. Immunity 45, 749-760 (2016).
105. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31-45 (2015).
106. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
107. Hadinegoro, S. R. et al. Efficacy and long-term safety of a Dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015).
108. Plotkin, S. A. The pertussis problem. Clin. Infect. Dis. 58, 830-833 (2014).
109. Ovsyannikova, I. G., Dhiman, N., Jacobson, R. M. & Poland, G. A. Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Expert Rev. Vaccines 5, 33-43 (2006).
110. Bomfim, I. L. et al. The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction. Genes Immun. 18, 75-81 (2017).
111. Tavira, B. et al. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65?induced immune response. Diabetologia 60, 1276-1283 (2017).
112. Larche, M. & Wraith, D. C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76 (2005).
113. Alhadj Ali, M. et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci. Transl. Med. 9, eaaf7779 (2017).
114. Afridi, S., Hoessli, D. C. & Hameed, M. W. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. Immunol. Rev. 272, 151-168 (2016).
115. Ludvigsson, J., Wahlberg, J. & Casas, R. Intralymphatic injection of autoantigen in type 1 diabetes. N. Engl. J. Med. 376, 697-699 (2017).
116. Clemente-Casares, X. et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530, 434-440 (2016).
117. Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126, 1224-1232 (2016).
118. Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18, 980-987 (2012).
119. Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189 (2015).
120. Chandran, S. et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants. Am. J. Transplant. 17, 2945-2954 (2017).
121. Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during human melanoma?T cell interactions. Nature 536, 91-95 (2016).
122. Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337-1341 (2016).
123. de Bakker, P. I. W. et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38, 1166-1172 (2006).
124. Dilthey, A., Cox, C., Iqbal, Z., Nelson, M. R. & McVean, G. Improved genome inference in the MHC using a population reference graph. Nat. Genet. 47, 682-688 (2015).
125. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291-296 (2012).
126. Zhou, F. S. et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. Nat. Genet. 48, 740-746 (2016).
127. Dolton, G. et al. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology 146, 11-22 (2015).
128. Sabatino, J. J. Jr, Huang, J., Zhu, C. & Evavold, B. D. High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J. Exp. Med. 208, 81-90 (2011).
129. Wekerle, H., Flugel, A., Fugger, L., Schett, G. & Serreze, D. Autoimmunity's next top models. Nat. Med. 18, 66-70 (2012).
130. Yu, D. et al. Roquin represses autoimmunity by limiting inducible T?cell co?stimulator messenger RNA. Nature 450, 299-303 (2007).